Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Suven Life Sciences said that the US Patent Office has granted second product patent for the class of selective Serotonin receptor affinity compounds discovered by Suven and are being developed as therapeutic agents.
Subscribe to our email newsletter
According to the invention of this patent disclosure, the compounds are useful in the treatment of neurodegenerative disorders like Alzheimer’s, Parkinson, Schizophrenia and Huntington’s.
Venkat Jasti, CEO of Suven, said: “We are very pleased by the issuance of this patent to Suven by US Patent office for our drug candidates that are being developed for CNS disorders which targets a $18 billion potential market opportunity.”